---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066971"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:18:17.326291+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics Q1 net loss $10.3M; positive RIVER trial results; CORAL data expected Q2 2025

## Summary
- Net loss of $10.3M ($10.9M YoY); R&D expenses $7.8M, G&A $3.7M.
- RIVER Phase 2a positive: 67% cough reduction from baseline, 57% placebo-adjusted (p<0.0001).
- CORAL Phase 2b enrollment completed Feb 2025; last patient visit Apr 2025; topline results on track for Q2 2025.
- Cash, equivalents and marketable securities $103.3M; runway expected into Q4 2026.

## SEC filing metadata
- accession: 0000950170-25-066971
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017025066971/0000950170-25-066971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017025066971/trvi-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066971
- JSON: https://secwatch.observer/filing/0000950170-25-066971.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.